Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma

Warning

This publication doesn't include Faculty of Sports Studies. It includes Central European Institute of Technology. Official publication website can be found on muni.cz.

Authors	RÉDOVÁ Martina POPRACH Alexandr NEKVINDOVÁ Jana ILIEV Robert RADOVÁ Lenka LAKOMÝ Radek SVOBODA Marek VYZULA Rostislav SLABÝ Ondřej
Year of publication	2012
Type	Article in Periodical
Magazine / Source	Journal of Translational Medicine
MU Faculty or unit	Central European Institute of Technology
Citation
Web	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3340316/?tool=pubmed
Doi	http://dx.doi.org/10.1186/1479-5876-10-55
Field	Oncology and hematology
Keywords	Renal cell carcinoma; MicroRNA; Serum; Biomarker
Description	There is no standard serum biomarker used for diagnosis or early detection of recurrence for renal cell carcinoma (RCC) patients. MicroRNAs (miRNAs) are abundant and highly stable in blood serum, and have been recently described as powerful circulating biomarkers in a wide range of solid cancers. Our aim was to identify miRNA signature that can distinguish the blood serum of RCC patients and matched healthy controls and validate identified miRNAs as potential biomarkers for RCC.
Related projects:	CEITEC - Central European Institute of Technology